

patrys

Corporate Overview:
12 June 2018

Safe Harbour Statement

The following material is for general information purposes only and is not to be relied upon for the making of an investment decision. Any investment in Patrys Limited ACN 123 055 363 (Patrys) is subject to investment risk including the possibility of loss of capital invested and no return of income or payment of dividends. Neither Patrys nor any other entity or person in or associated with the Patrys group of companies guarantees any return (whether capital or income) or generally the performance of Patrys or the price at which its securities may trade.

In particular, this presentation is not a recommendation, offer or invitation to subscribe for or purchase Patrys securities. It is not for general distribution or third party reliance or use. While it has been prepared from sources Patrys believe to be reliable, Patrys cannot guarantee its accuracy or completeness and undertakes no obligation to advise of changes or updates to any such materials.

These materials are not exhaustive of all of the information a potential investor or their professional adviser would require. Nor do these materials take into account any specific objectives, financial situation or needs of investors. In addition, the past performance of Patrys cannot be assumed as indicative of the future performance of the company. For these and other reasons, before making any investment decision regarding Patrys securities you are strongly recommended to obtain your own up to date independent legal, financial and investment advice – those acting without such advice do so at their own risk.

Where this presentation does contain any forward looking statements, those statements are only made as the date of the presentation and are to be considered “at-risk statements” not to be relied upon as they are subject to further research and to known and unknown risks, uncertainties and other factors that may lead to actual results differing from any forward looking statement. This is particularly the case with companies such as Patrys which operate in the field of researching, discovering, developing, and commercialising potential drugs intended for safe and effective for human treatments or therapies.


Vision

Patrys is a biopharmaceutical company devoted to the development and commercialisation of novel antibody technologies to improve the clinical outcomes for cancer patients




Two platforms, multiple opportunities

- Two Antibody Platforms
 1. Deoxymabs – unique positioning at the convergence of two transformative anti-cancer technologies; antibodies and DDR therapies
 2. IgMs – completed trials show safety and signals of efficacy, **partnered**
- Differentiated by multiple opportunities for shareholder returns via development and partnering
- Streamlined operations, low cash burn, non-dilutive funding opportunities
- Value being built and **realised**
- Proven Board and Management



Development Pipeline



Nexus of two transformative anti-cancer therapies

Antibodies (Abs or mAbs)

- Bind cancer antigens
- Various strategies for use
- Used in brain, breast, CLL, colorectal, head and neck, Hodgkin's and Non-Hodgkin's lymphomas, lung, melanoma, prostate and stomach cancers
- Fewer side effects than small molecules
- Estimated Cancer Ab market in 2017 is US\$33B*



Deoxymab 3E10

DNA damage response (DDR)

- Uncorrected DNA damage can lead to cancer
- DDR protects cells from DNA damage
- Faulty DDRs allow cancer to develop
- DDR inhibition blocks 'back up' DDR systems, causing cancer cell death
- Healthy cells are resistant to DDR inhibition
- PARP inhibitors approved from 2014

* <https://www.transparencymarketresearch.com/monoclonal-antibody-therapeutics-market.html>


Deoxymab 3E10

- Deoxymab 3E10 is a DNA damage response (DDR) therapeutic antibody
- First in class, synergizes with PARP (DDR) inhibitor
- Proven utility as a molecular delivery vehicle
- Previous Phase 1 clinical trial in lupus* showed no safety issues
- Anti-cancer applications licensed from Yale University
- Patrys is developing PAT-DX1, a humanised version of Deoxymab 3E10, to target solid tumors, particularly glioblastoma, pancreatic, breast and ovarian




*Spertini *et al.*, Idiotypic vaccination with a murine anti-dsDNA antibody: phase I study in patients with nonactive systemic lupus erythematosus with nephritis. J. Rheumatol. 1999;26:2602–2608

Novel Mechanism of Action




3E10 binds to extracellular DNA then is transported across the plasma membrane via the equilibrative nucleoside transporter (ENT2) pathway

3E10 translocates into the nucleus




3E10 binds to nuclear DNA and inhibits DNA repair



Multiple Development Paths.....

Single agent for DNA repair associated cancers (BRCA- or PTEN-)

Conjugated with nanoparticles for targeted delivery of chemotherapeutics




Enhances efficacy of radiation therapy




Enhances efficacy of some chemotherapies

...Supported by Strong Pre-clinical Science


Pancreatic BRCA2- cancer xenograft




Breast cancer xenograft



Glioma cancer xenograft



Glioma cancer cells




Research Partnered with Yale University

- James E. Hansen, MD (Principal Investigator)
 - Assistant Professor, Department of Therapeutic Radiology, Yale School of Medicine
 - Physician-scientist and practicing radiation oncologist specialising in treatment of cancers of the brain, head and neck, lung, skin, and lymphatic system
 - 14+ years of experience working with 3E10 and other cell-penetrating Abs
 - Lead inventor on patents pertaining to use of Deoxymabs against cancer




PAT-DX1 – Humanised Lead Candidate


- Optimised for efficacy, manufacturability and novelty
- Novel IP position
- Positive results in multiple pre-clinical studies
 - ✓ Kills colon cancer cells that lack key DNA repair enzymes (BRCA2)
 - ✓ Active against primary human glioblastoma explants from patients
 - ✓ Efficacy indicated in animal model of triple negative breast cancer
 - ✓ Synergizes with PARP inhibitor
 - ✓ Crosses blood brain barrier, reduces tumour size and increases survival in orthotopic glioblastoma model
 - ✓ Targets and kills glioblastoma cancer stem cells



PAT-DX1 in Model of MGMT-Unmethylated GBM Derived from Human Tumour Explants




- Dark staining is glioblastoma, light staining is healthy brain tissue
- Translates as survival benefit



3E10 and PAT-DX1 Nanoparticle Conjugates

- Yale University has developed technology to link 3E10 or PAT-DX1 to nanoparticles (NPs) that can be loaded with chemotherapeutic (or other) drugs
- By linking 3E10 or PAT-DX1 to NPs, the conjugated molecule is preferentially attracted to tumor tissues and delivers its payload specifically to tumors. Studies with 3E10-NP showed significantly increased efficacy of drug therapy
- PAT-DX1-NPs localize to xenograft tumors when compared to unconjugated NPs
- PAT-DX1-NPs also localize to axillary lymph node metastases, meaning that an eventual therapeutic could treat both primary and secondary tumors – potentially before the latter had even been identified

PAT-DX1-NP localisation in mice with triple negative breast cancer tumors



Free NPs PAT-DX1-NPs PAT-DX1-NPs

PAT-DX1-NP shows enhanced localisation of primary tumors (blue circles) and localisation of apparent axillary lymph node metastases (red circles)


Recent Pre-clinical Cancer Antibody Deals

Date	Tech	Seller	Buyer	Total (USD)	Up Front (USD)
Feb-14	Nanobody platform	Ablynx	Merck	6.5B	27 M
Jan-15	Checkpoint regulators: GITR, OX40, LAG-3 and TIM-3	Agenus	Incyte	410M	60M
Aug-15	Anti-GDF15 MAb	Aveo Oncology	Novartis	326M	15M
Oct-15	Anti-TGF-beta MAb	Xoma	Novartis	480M	37M
Jan-16	Cell-penetrating alphabodies*	Complix	Merck	280M	N/A
May-16	Bi-specific Ab, alternative to CAR-T	Macro-Genics	Janssen	740M	75M
Jul-16	4 early stage Abs	Jounce	Celgene	2.6B	261M
Jun-17	Intracellular delivery platform	Feldan/Elasmogen	Amgen	N/A	N/A
Nov-17	Bi-specific antibody platform	Zymeworks	J&J	332M	50M
April-18	Bi-specific antibody platform	Compugen	Astra Zeneca	210M	10M
April-18	Checkpoint inhibitor: OSE-172 a SIRP alpha antagonist	OSE Immunotherapeutics	Boehringer Ingelheim	1.4B	18.4M

*Collaboration expanded in 2017

IgM Overview


- Body's first line of defence as part of the innate immune response
- Demonstrated anti-tumour activity in both mice and humans
- Excellent safety profile in humans
 - reduced side effects
- Combination with existing chemotherapeutic treatments potentially without any cumulative toxicology effects
- Able to be manufactured to commercial scale
- 3 antibodies selected for out-licensing under business development program



Initial Therapeutic Candidate, PAT-SC1 – Out-licensed

Current Stage/Competition:

- Hefei Co-source licensed rights to PAT-SC1 for China in 2015
- Hefei currently pursuing CHO cell line development work
- Orphan designation by the FDA for use in gastric cancer
- No other known clinical products targeting CD55



Experienced Board



John Read Chairman

- Experienced Chairman and Director in public, private and government organisations
- Extensive career in venture capital, private equity and commercialisation
- Chairman of CVC Limited (ASX: CVC), previously Eildon Capital Limited (ASX:EDC)



James Campbell

- >20 years of international biotechnology research, management and leadership
- Previously the CFO and COO of ChemGenex Pharmaceuticals Limited (ASX:CXS) and of Evolve Biosystems Inc.



Mike Stork

- Managing Director of Stork Holdings Ltd, active in Canadian technology start-up sector
- Director of a number of leading Canadian technology start-up companies



Suzy Jones

- Founder and Managing Partner of DNA Ink, a life sciences advisory firm in San Francisco
- 20 years at Genentech in BD, product development and immunology research - including managing the Rituxan team, the first Mab launched to treat cancer

Scientific Advisory Board



Dr Pamela M. Klein

- Medical training, then U.S. National Cancer Institute
- Vice President, Development at Genentech, led development of a large portfolio of drugs including all the HER (Herceptin, Tarceva, Perjeta), Apoptosis (antibodies and small molecules) and Hematology compounds
- Chief Medical Officer of Intellikine (acquired by Millennium/Takeda)
- Advisor to a range of different biotech and investment companies, with roles on Scientific Advisory Boards and Corporate Boards



Dr Allen Ebens

- PhD at UCLA and a Post-Doc at UCSF
- 5 years with Exelixis in the Discovery Biology group
- 11 years at Genentech in the Research Oncology working from concept to clinic across multiple therapeutic platforms including antibodies, small molecule drugs, antibody-drug conjugates, and cell-based therapies
- Established the oncology research lab at Juno Therapeutics
- Currently Senior Director, Immune Oncology at NGM Biopharmaceuticals

Financial Snapshot


Financial Parameter	Measurement
ASX: PAB	1,073 million shares
Daily volume (3 mth ave):*	11.6 million shares
Market Capitalization:*	\$54.6 million
Cash held:**	\$7.4 million
Net burn rate:	\$1.3 million in 2016-17

* Effective 8 June, 2018

** \$2.8 M reported as at 31 March, 2018. Placement of \$4.6M completed on 23 May 2018

Supported by Potential Assets

- Ongoing insurance claims
 - Pursuing insurance claims related to the failed manufacturing run of PAT- SM6 in 2014/15
 - \$1,272,332 in insurance recoveries received in 2015
 - Given the magnitude, number and complexity of the claims this is a protracted process



Delivered Against 2017 Objectives

- Completion of *in silico* design and optimisation of 3E10 ✓
- Pre-clinical testing of multiple Deoxymab 3E10 candidates ✓
- Lead candidate selection for Deoxymab 3E10 program ✓
- Pre-clinical data and publications on Abs and targets ✓
- Ongoing development of PAT-SC1 (via strategic alliance) ✓
- Additional alliances and collaborations ✓

Looking Ahead

DX1-nanoparticle delivery – breast cancer animal data	Jan 2018	✓
DX1-nanoparticle tumor localization – breast cancer	Jan 2018	✓
DX1 ability to cross the blood brain barrier – brain cancer	Feb 2018	✓
DX1 in combination with PARPi – brain cancer animal data	Mar 2018	✓
Dynamics of DX1-nanoparticle in brain cancer	May 2018	✓
DX1 pharmacokinetics in triple negative breast cancer	June 2018	
Initiate stable cell line development of PAT-DX1	H2 2018	
DX1 - Solid cancer (TBC) animal data	August 2018	
Select target indication for PAT-DX1 clinical development	Q3 2018	
DX1 – Additional solid cancer (TBC) animal data	October 2018	
DX1 + Temozolomide + radiation – brain cancer animal data	Q4 2018	
New IP filings and patent grants	Ongoing	
Collaborations	Ongoing	✓

For Further Information

Contact Details:

Dr. James Campbell

Chief Executive Officer and Managing Director

Ph: +61 3 9670 3273

Email: info@patrys.com

Website: www.patrys.com